Proteomics Profiling Identifies MCM4 as a Prognostic Biomarker for Postoperative Metastasis in Solid Pseudopapillary Neoplasms of the Pancreas

Key Points

• MCM4 as a significant prognostic biomarker indicates relationship with postoperative metastasis.
• The study shows a 75% accuracy in predicting metastasis associated with MCM4 levels.
• Assessment using proteomics profiling enhances identification of critical biomarkers in pancreatic tumors.
• Findings highlight MCM4's potential role in guiding postoperative treatment strategies for neoplasms.